WHF Global Study on CVD and COVID-19

In order to better understand the intersection between cardiovascular disease and COVID-19, the World Heart Federation has embarked on a global study which aims to better describe cardiovascular outcomes and identify cardiovascular risk factors associated with poor prognosis in patients with COVID-19.

This global cohort study on COVID-19 and cardiovascular outcomes and risk factors is already underway, with sites recruiting patients in Argentina, Bosnia and Herzegovina, Brazil, Ghana, India, Iran, Japan, Kenya, Nigeria, Pakistan, Portugal, South Africa and Sudan. WHF encourages participation from every corner of the world for this important global study.

WHF invited all our Members to identify and endorse at least two hospitals or other medical facilities (recruiting centres) in their respective countries. Each centre will aim to recruit between 50 and 200 COVID-19 patients. There is no limit in the number of sites that can take part. The data entry for each patient takes 15-20 minutes and is entered using REDCap.

Once a site is confirmed as appropriate for the study, a site initiation meeting is organized by the Study Coordination team in India (Public Health Foundation India) to provide an introduction to the study. The study coordination team oversees all sites in the study and is available to assist throughout the duration of the study.

The Global study will disseminate preliminary data on cardiovascular outcomes among patients hospitalized with COVID-19 in late 2020, with the final analysis to be published in 2021.